98%
921
2 minutes
20
Purpose: Hepatocellular carcinoma (HCC) recurrence remains a significant burden on global healthcare. Hepatic ischemia-reperfusion injury (HIRI) is a common complication in liver surgery and may be a contributing factor to HCC recurrence. Nevertheless, the potential mechanism underlying HIRI-induced HCC recurrence has not been fully elucidated. Herein, by combining bioinformatics approaches and basic experimental research, CKS2 was preliminarily identified as a crucial factor involved in HIRI-induced HCC recurrence potentially by modulating M2 macrophages.
Methods: Through performing Weighted Gene Co-Expression Network Analysis (WGCNA), differential gene expression analysis, and screening for genes associated with disease-free survival (DFS) on large-scale genomics projects including The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO), the pivotal role of CKS2 in HIRI-induced HCC recurrence was determined. The clinical significance, single-cell analysis, immune cell infiltration correlation, functional enrichment, mutation landscape, and drug sensitivity of CKS2 in HCC were further characterized. Finally, CKS2 expression and function were validated through experimental techniques such as flow cytometry, immunohistochemistry, Western blot assay and quantitative real-time PCR (qRT-PCR).
Results: The expression of CKS2 was significantly upregulated in HIRI and HCC tissues and was closely associated with adverse clinical outcomes in HCC patients. There was a positive correlation between CKS2 expression and tumor stemness characteristics. Additionally, high CKS2 expression was strongly linked to M2 macrophage infiltration in HCC tissues. And drug sensitivity analysis indicated that HCC patients with high CKS2 expression were prone to develop drug resistance, complicating clinical anti-tumor treatment. Ultimately, the expression pattern of CKS2 and its correlation with M2 macrophages in HCC were confirmed through experimental validation.
Conclusion: CKS2 was identified as a key factor in HIRI-induced HCC recurrence and was critically associated with M2 macrophage infiltration abundance, providing novel insights and a direction for future research.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12405721 | PMC |
http://dx.doi.org/10.2147/JIR.S543147 | DOI Listing |
Ann Surg Oncol
September 2025
Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Background: Postoperative late recurrence (POLAR) after 2 years from the date of surgical resection of hepatocellular carcinoma (HCC) represents a unique surveillance and management challenge. Despite identified risk factors, individualized prediction tools to guide personalized surveillance strategies for recurrence remain scarce. The current study sought to develop a predictive model for late recurrence among patients undergoing HCC resection.
View Article and Find Full Text PDFFront Pharmacol
August 2025
The Second Affiliated Hospital of Zhejiang Chinese Medical University, TCM Hepatology Department, Hangzhou, China.
Hepatocellular carcinoma (HCC) is a prevalent malignant neoplasm of the digestive system, including 80% of primary liver malignancies. The Wnt/β-catenin signaling pathway plays a key role in immune response and tumer resistance. A growing number of studies have shown that the Wnt/β-catenin signaling pathway is involved in the pathogenesis of HCC.
View Article and Find Full Text PDFAnn Surg Oncol
September 2025
Department of Gastroenterological and Transplant Surgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Background: Hepatocellular carcinoma (HCC) frequently invades the portal vein, leading to early recurrence and a poor prognosis. However, the mechanisms underlying this invasion remain unclear. In this study, we aimed to detect portal vein circulating tumor cells (CTCs) using a Glypican-3-positive detection method and evaluate their prognostic significance.
View Article and Find Full Text PDFJ Viral Hepat
October 2025
Medical Practice Evaluation Center, Massachusetts General Hospital, Boston, Massachusetts, USA.
Discontinuing antivirals in chronic hepatitis B virus (HBV) 'e' antigen negative infection can enhance HBV surface antigen (HBsAg) loss but risks complications. We modelled the clinical impact of discontinuing antivirals in chronic HBV. We developed a Markov state model with Monte Carlo simulation of chronic HBV to compare continuation of antiviral therapy with 3 strategies of cessation and reinitiation for: (1) virologic relapse, (2) clinical relapse, or (3) hepatitis flare.
View Article and Find Full Text PDFBackground: Since 2013, we have performed conversion surgery after hepatic arterial infusion chemotherapy (HAIC) for initially unresectable locally advanced hepatocellular carcinoma (LA-HCC).
Methods: Between 2013 and 2021, we assessed the surgical and oncological outcomes and pathological findings of patients with LA-HCC without extrahepatic spread (EHS) whose tumors converted from unresectable to resectable status with the New-FP regimen HAIC.
Results: We censored 153 patients with LA-HCC (Child-Pugh A, without EHS) indicated for HAIC.